Vaginal estradiol for GSM: the most under-prescribed protocol in women's health

Half of postmenopausal women have meaningful symptoms of genitourinary syndrome of menopause — dryness, painful sex, urinary urgency, recurrent UTIs, and the slow disappearance of comfortable tissue down there.

Roughly 7% are on the protocol that resolves it.

That gap — between symptom prevalence and treatment rate — is the largest in any common condition in women's health. And the gap isn't because the treatment is risky, expensive, or hard to access. It's because nobody is talking about it. Most women suffer through it for a decade thinking it's just "part of getting older." Most primary-care providers don't bring it up. Most gynecologists wait until the patient does.

Here's the clinical case for the most under-prescribed protocol in women's health.

What GSM actually is.

Genitourinary syndrome of menopause was formally named in 2014 by the International Society for the Study of Women's Sexual Health and NAMS, replacing the older terms "vaginal atrophy" and "atrophic vaginitis." The rename mattered because the old terms only captured part of what was happening.

GSM covers a cluster of symptoms driven by the loss of estradiol's effect on tissues that have estrogen receptors:

• Vaginal: dryness, burning, itching, painful intercourse (dyspareunia), thinning of the vaginal walls
• Urinary: urgency, frequency, recurrent urinary tract infections, mild stress incontinence
• Vulvar: loss of fullness, irritation, sensitivity changes

All of these tissues — vaginal, vulvar, urethral, bladder trigone — are estrogen-responsive. When estradiol drops in menopause, the tissue thins, blood flow decreases, the vaginal pH shifts, the local microbiome changes, and the cluster of symptoms shows up.

Unlike hot flashes, which usually fade within 4–7 years, GSM is progressive. It doesn't go away on its own. Left untreated, it gets worse over time as the tissue continues to atrophy.

Why systemic HRT often isn't enough.

A common assumption: "I'm on the estradiol patch — that should cover it."

It usually doesn't. Systemic HRT (patch, gel, oral) raises serum estradiol enough to address hot flashes, bone density, and mood — but the concentration that actually reaches vaginal and urinary tissues is too low for many women to fully resolve GSM. Roughly 40% of women on systemic HRT still have meaningful local symptoms.

That's where local vaginal estradiol comes in.

How local vaginal estradiol works.

Vaginal estradiol is applied directly to the affected tissue — as a cream, ring, tablet, or insert. It works locally where the tissue lives, with minimal systemic absorption at standard doses.

How minimal? The leading published studies show that women on low-dose vaginal estradiol (10 mcg tablets twice weekly, for example) have serum estradiol levels essentially indistinguishable from postmenopausal baseline — well within the range a clinician would expect without any therapy at all.

The clinical effect is dramatic. Tissue thickness, vaginal pH, local blood flow, and patient-reported symptoms all improve meaningfully within 2–4 weeks, with continued improvement out to 12 weeks. The North American Menopause Society 2020 position statement on GSM gives vaginal estradiol the strongest possible recommendation — "first-line therapy" for GSM symptoms not adequately controlled by non-hormonal moisturizers.

What the typical protocol looks like.

There are four main delivery formats, all equally effective when used correctly:

• Estradiol cream (Estrace, or compounded estriol/estradiol) — applied with an applicator at bedtime, 2 grams nightly for 2 weeks (loading), then 1 gram 2-3x weekly (maintenance). The most commonly compounded option at DirectCare AI because dosing flexibility is unmatched.
• Estradiol vaginal tablets (Vagifem, 10 mcg) — inserted nightly for 2 weeks, then twice weekly. Mess-free, predictable dosing.
• Estradiol vaginal insert (Imvexxy, 4 or 10 mcg) — same pattern as tablets.
• Vaginal ring (Estring) — silicone ring inserted vaginally, releases low-dose estradiol over 90 days. The lowest-touch option — insert and forget.

All four reach therapeutic local concentrations. The choice is purely about lifestyle preference.

Compounded estriol-and-estradiol cream

Many DirectCare AI patients land on a compounded bi-est (estriol + estradiol) cream. The clinical case for this option:

• Estriol is the gentler of the body's three estrogens. Locally applied estriol produces meaningful tissue effects with even less systemic absorption than estradiol alone.
• Compounded dosing means your clinician can titrate to the exact concentration that works for you — useful for women who get irritation from standard formulations, or who don't fully respond to commercial products.
• Cost for compounded vaginal estrogen is typically lower than branded vaginal tablets or rings.

Realistic expectations.

• Week 2: Most women notice meaningfully less dryness. Some early easing of urinary urgency.
• Week 4-6: Painful sex usually resolves or is dramatically reduced. Recurrent UTI cycles typically begin to break.
• Week 8-12: Full tissue restoration in most patients. Vaginal pH normalizes (from the menopausal range of 6+ back toward the premenopausal 4-4.5).
• Maintenance: Continuing the protocol indefinitely. If you stop, the tissue regresses within 2-3 months.

Why so few women are on it.

The treatment-rate gap (50% of women symptomatic, ~7% treated) traces to a few familiar causes:

• Patients don't bring it up. GSM symptoms are intimate and embarrassing to discuss in a 15-minute primary-care appointment, especially with a male provider or one the patient doesn't know well.
• Providers don't ask. Most primary-care visits don't have GSM screening built in. Even gynecology visits, in many practices, don't proactively address GSM unless the patient raises it.
• Confusion about systemic HRT risks. Patients (and some providers) read "estrogen" and apply the 20-year-old Women's Health Initiative risk concerns to local estrogen — even though the WHI was about systemic conjugated estrogens, not low-dose local estradiol, and the safety profiles are not comparable.
• Insurance friction. Some plans require step therapy through non-hormonal moisturizers (which usually don't fully resolve GSM) before covering vaginal estrogen.

What about non-hormonal options?

Vaginal moisturizers (Replens, hyaluronic acid suppositories) and lubricants are real and useful. They address symptoms without changing the underlying tissue. For women with mild GSM or contraindications to estrogen, they can be the primary therapy.

But for moderate-to-severe GSM, the comparison is not close. Moisturizers help. Vaginal estradiol restores. Most women who try both end up on the local estrogen — and stay on it.

When to talk to a clinician

If any of these is true, GSM is worth a conversation:

• Sex is regularly uncomfortable
• You're having more UTIs than you used to
• Tissue feels thinner, drier, more sensitive than it did 5 years ago
• You're on systemic HRT but still have local symptoms
• You stopped having sex because of these symptoms

Pair this with the full HRT picture in HRT after 40: what actually changes and progesterone at night for the systemic side of the conversation.

Half of postmenopausal women have these symptoms. Seven percent are on the treatment that fixes them. The single biggest under-served opportunity in women's health is a 30-second prescription away.

Sources: International Society for the Study of Women's Sexual Health & NAMS 2014 GSM definition; NAMS 2020 position statement on GSM; ACOG Committee Opinion on vaginal estrogen in women with breast cancer history.

Editorial disclosure: This article is for informational purposes only and does not constitute medical advice. All treatments at DirectCare AI are prescribed by US-licensed clinicians based on individual medical evaluation. Compounded medications are not FDA-approved as finished products; their active ingredients are individually FDA-approved. Always consult a US-licensed clinician before starting or changing any therapy.